Key Highlights
- TEM shares decline 1.66% following FDA clearance for xT CDx platform
- Early session momentum evaporates as Tempus AI stock reverses gains
- FDA grants approval for tumor-only cancer genomic profiling test
- Tempus AI becomes first lab with dual-format CDx approval
- Stock retreats to $50.44 after touching near $55 intraday
Shares of Tempus AI (TEM) declined despite receiving significant regulatory clearance from the FDA for its xT CDx cancer diagnostic platform. The stock closed at $50.44, falling $0.85, representing a 1.66% decrease. Earlier in the session, TEM climbed close to $55 before sellers dominated and wiped out the morning’s gains.
Early Session Strength Evaporates for TEM
Tempus AI began trading with notable upward momentum following the company’s announcement of fresh FDA clearance. Yet this positive movement weakened considerably as the session unfolded. By late morning, TEM had shifted into negative territory.
The equity’s decline represented a dramatic turnaround from its intraday peak near $55. This reversal pushed TEM below its earlier session strength. The price action maintained downward pressure throughout the day despite the positive regulatory development.
Tempus AI operates on the Nasdaq exchange with ticker symbol TEM. The organization specializes in developing artificial intelligence-powered solutions for precision medicine applications. This recent FDA authorization provides an additional regulated product offering within its oncology diagnostics segment.
Regulatory Approval for Tumor-Only Genomic Profiling
The FDA granted clearance for a tumor-only indication of the Tempus xT CDx platform. This diagnostic system employs next-generation sequencing technology to perform genomic profiling across solid tumor malignancies. The new authorization extends the test’s capabilities beyond its previous requirement for tumor-normal sample pairs.
According to Tempus, this approval establishes the laboratory as the first to receive FDA companion diagnostics clearance for both testing configurations. These configurations encompass both tumor-only and tumor-normal comprehensive genomic profiling methodologies. The decision provides physicians with greater options when matched normal tissue samples cannot be obtained.
The xT CDx diagnostic examines 648 genes within tumor tissue specimens. It identifies substitutions, insertions, deletions, along with microsatellite instability markers. The platform also enables molecular profiling for individuals previously diagnosed with solid malignant tumors.
Reimbursement Strategy and Clinical Applications
Tempus connected this regulatory milestone to its broader reimbursement objectives. The organization indicated it can now transition its DNA solid tumor testing portfolio toward FDA-cleared assay status. Additionally, these products can be incorporated under its existing ADLT pricing structure.
Chief Financial Officer Jim Rogers noted the approval facilitates consolidated ADLT pricing across the solid tumor DNA portfolio. Rogers also projected Tempus anticipates roughly $200 in average selling price improvement starting in 2027. The company attributed this anticipated financial benefit directly to this regulatory clearance.
The Tempus xT CDx platform additionally functions as a companion diagnostic for colorectal cancer therapeutic selection. The test identifies patients who might respond favorably to Erbitux and Vectibix treatments. Consequently, the approval broadens clinical utility even as TEM shares recorded a session loss.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
